AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes
A Randomised, Multi-Centre, Phase IV, Double-Blind, Parallel Group Study Comparing the Effects of 52 Weeks Administration of AVANDAMET and Metformin Plus Sulphonylurea on Change in HbA1c From Baseline in Overweight Type 2 Diabetics Poorly Controlled on Metformin.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Brugge, Belgium, 8000
- GSK Investigational Site
-
Bruxelles, Belgium, 1030
- GSK Investigational Site
-
Bruxelles, Belgium, 1210
- GSK Investigational Site
-
Heverlee, Belgium, 3001
- GSK Investigational Site
-
Landen, Belgium, 3400
- GSK Investigational Site
-
Namur (Champion), Belgium, 5020
- GSK Investigational Site
-
Oostham, Belgium, 3945
- GSK Investigational Site
-
Petit-Rechain, Belgium, 4800
- GSK Investigational Site
-
Tessenderlo, Belgium, 3980
- GSK Investigational Site
-
Tremelo, Belgium, 3120
- GSK Investigational Site
-
Willebroek, Belgium, 2830
- GSK Investigational Site
-
Zandhoven (Pulle), Belgium, 2243
- GSK Investigational Site
-
-
-
-
-
Anzin, France, 59410
- GSK Investigational Site
-
Briollay, France, 49125
- GSK Investigational Site
-
Commelle Vernay, France, 42120
- GSK Investigational Site
-
Cremeaux, France, 42260
- GSK Investigational Site
-
Evron, France, 53600
- GSK Investigational Site
-
Laval, France, 53000
- GSK Investigational Site
-
Louverne, France, 53950
- GSK Investigational Site
-
Lyon, France, 69007
- GSK Investigational Site
-
Paris, France, 75015
- GSK Investigational Site
-
Roanne, France, 42300
- GSK Investigational Site
-
Saint Ouen, France, 93400
- GSK Investigational Site
-
Sainte Suzanne, France, 53270
- GSK Investigational Site
-
Segré, France, 49500
- GSK Investigational Site
-
Venissieux, France, 69200
- GSK Investigational Site
-
-
Nord-Pas-de-Calais
-
Roubaix, Nord-Pas-de-Calais, France, 59100
- GSK Investigational Site
-
-
-
-
Baden-Wuerttemberg
-
Gueglingen, Baden-Wuerttemberg, Germany, 74363
- GSK Investigational Site
-
Kippenheim, Baden-Wuerttemberg, Germany, 77971
- GSK Investigational Site
-
Koenigsfeld, Baden-Wuerttemberg, Germany, 78126
- GSK Investigational Site
-
Waldshut-Tiengen, Baden-Wuerttemberg, Germany, 79961
- GSK Investigational Site
-
Weinheim, Baden-Wuerttemberg, Germany, 69469
- GSK Investigational Site
-
-
Bayern
-
Grafing, Bayern, Germany, 85567
- GSK Investigational Site
-
Herzogenaurach, Bayern, Germany, 91074
- GSK Investigational Site
-
Immenstadt, Bayern, Germany, 87509
- GSK Investigational Site
-
Oberteisendorf, Bayern, Germany, 83317
- GSK Investigational Site
-
Saaldorf-Surheim, Bayern, Germany, 83416
- GSK Investigational Site
-
Wallerfing, Bayern, Germany, 94574
- GSK Investigational Site
-
Wuerzburg, Bayern, Germany, 97072
- GSK Investigational Site
-
-
Hessen
-
Grossalmerode, Hessen, Germany, 37247
- GSK Investigational Site
-
-
Niedersachsen
-
Einbeck, Niedersachsen, Germany, 37574
- GSK Investigational Site
-
Hannover, Niedersachsen, Germany, 30519
- GSK Investigational Site
-
Isernhagen, Niedersachsen, Germany, 30916
- GSK Investigational Site
-
Papenburg, Niedersachsen, Germany, 26871
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Beckum, Nordrhein-Westfalen, Germany, 59269
- GSK Investigational Site
-
Bergkamen-Rünthe, Nordrhein-Westfalen, Germany, 59192
- GSK Investigational Site
-
Bochum, Nordrhein-Westfalen, Germany, 44869
- GSK Investigational Site
-
Dinslaken, Nordrhein-Westfalen, Germany, 46537
- GSK Investigational Site
-
Dortmund, Nordrhein-Westfalen, Germany, 44137
- GSK Investigational Site
-
Essen, Nordrhein-Westfalen, Germany, 45359
- GSK Investigational Site
-
Essen, Nordrhein-Westfalen, Germany, 45134
- GSK Investigational Site
-
Goch, Nordrhein-Westfalen, Germany, 47574
- GSK Investigational Site
-
Koeln, Nordrhein-Westfalen, Germany, 51069
- GSK Investigational Site
-
Viersen, Nordrhein-Westfalen, Germany, 41749
- GSK Investigational Site
-
-
Rheinland-Pfalz
-
Mainz, Rheinland-Pfalz, Germany, 55116
- GSK Investigational Site
-
Neuwied, Rheinland-Pfalz, Germany, 56564
- GSK Investigational Site
-
Rhaunen, Rheinland-Pfalz, Germany, 55624
- GSK Investigational Site
-
Speyer, Rheinland-Pfalz, Germany, 67346
- GSK Investigational Site
-
-
Saarland
-
Saarlouis, Saarland, Germany, 66740
- GSK Investigational Site
-
-
Sachsen
-
Dresden, Sachsen, Germany, 01219
- GSK Investigational Site
-
-
Sachsen-Anhalt
-
Wolmirstedt, Sachsen-Anhalt, Germany, 39326
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Elmshorn, Schleswig-Holstein, Germany, 25335
- GSK Investigational Site
-
-
-
-
-
Blanchardstown, Ireland, 15
- GSK Investigational Site
-
Dublin, Ireland, 8
- GSK Investigational Site
-
Dublin, Ireland, 9
- GSK Investigational Site
-
-
-
-
Emilia-Romagna
-
Bologna, Emilia-Romagna, Italy, 40138
- GSK Investigational Site
-
Ferrara, Emilia-Romagna, Italy, 44100
- GSK Investigational Site
-
Ravenna, Emilia-Romagna, Italy, 48100
- GSK Investigational Site
-
-
Liguria
-
Arenzano (GE), Liguria, Italy, 16011
- GSK Investigational Site
-
Genova, Liguria, Italy, 16132
- GSK Investigational Site
-
-
Sardegna
-
Sassari, Sardegna, Italy, 07100
- GSK Investigational Site
-
-
Umbria
-
Città di Castello (PG), Umbria, Italy, 06012
- GSK Investigational Site
-
Terni, Umbria, Italy, 05100
- GSK Investigational Site
-
-
-
-
-
Kaunas, Lithuania, LT-44320
- GSK Investigational Site
-
Kaunas, Lithuania, LT-49335
- GSK Investigational Site
-
Vilnius, Lithuania, LT-08661
- GSK Investigational Site
-
Vilnius, Lithuania, LT-07156
- GSK Investigational Site
-
-
-
-
-
Durango, Mexico, 3400
- GSK Investigational Site
-
Mexico, D.F., Mexico, 11850
- GSK Investigational Site
-
-
Baja California Norte
-
Tijuana, Baja California Norte, Mexico, 22320
- GSK Investigational Site
-
-
Hidalgo
-
Pachuca, Hidalgo, Mexico, 42039
- GSK Investigational Site
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44340
- GSK Investigational Site
-
-
-
-
-
Beek En Donk, Netherlands, 5741 CG
- GSK Investigational Site
-
Beerzerveld, Netherlands, 7685 PG
- GSK Investigational Site
-
Den Haag, Netherlands, 2582 LJ
- GSK Investigational Site
-
Heerlen, Netherlands, 6416 EG
- GSK Investigational Site
-
Hoogvliet, Netherlands, 3192 JN
- GSK Investigational Site
-
Landgraaf, Netherlands, 6373 JS
- GSK Investigational Site
-
Musselkanaal, Netherlands, 9581 AJ
- GSK Investigational Site
-
Oude Pekela, Netherlands, 9665 AR
- GSK Investigational Site
-
Spijkenisse, Netherlands, 3207 NB
- GSK Investigational Site
-
Woerden, Netherlands, 3443 GG
- GSK Investigational Site
-
Zaandam, Netherlands, 1504 JA
- GSK Investigational Site
-
Zieuwent, Netherlands, 7136 KH
- GSK Investigational Site
-
-
-
-
-
Alcobendas/Madrid, Spain, 28100
- GSK Investigational Site
-
Alcora/Castellón, Spain, 12110
- GSK Investigational Site
-
Alicante, Spain
- GSK Investigational Site
-
Alzira, Spain, 46600
- GSK Investigational Site
-
Artana/Castellón, Spain, 12527
- GSK Investigational Site
-
Barcelona, Spain, 08022
- GSK Investigational Site
-
Barcelona, Spain, 08015
- GSK Investigational Site
-
Benicassim (Castellon), Spain
- GSK Investigational Site
-
Cadiz, Spain, 11009
- GSK Investigational Site
-
Castellón, Spain
- GSK Investigational Site
-
Cáceres, Spain, 10004
- GSK Investigational Site
-
Gerona, Spain
- GSK Investigational Site
-
Granada, Spain, 18014
- GSK Investigational Site
-
Madrid, Spain, 28041
- GSK Investigational Site
-
Madrid, Spain, 28046
- GSK Investigational Site
-
Madrid, Spain, 28034
- GSK Investigational Site
-
Madrid, Spain, 28037
- GSK Investigational Site
-
Malaga, Spain, 29009
- GSK Investigational Site
-
Merida, Spain, 6800
- GSK Investigational Site
-
Móstoles/Madrid, Spain, 28935
- GSK Investigational Site
-
Onda (Castellon), Spain
- GSK Investigational Site
-
Pontevedra, Spain, 36002
- GSK Investigational Site
-
Sabadell (Barcelona), Spain, 08208
- GSK Investigational Site
-
San Juan De Alicante, Spain, 3550
- GSK Investigational Site
-
Sta Coloma de Gramanet (Barcelona), Spain, 08923
- GSK Investigational Site
-
Tarrasa, Barcelona, Spain, 08221
- GSK Investigational Site
-
Valencia, Spain, 46010
- GSK Investigational Site
-
-
-
-
-
Bern, Switzerland, 3007
- GSK Investigational Site
-
Emmenbrücke, Switzerland, 6020
- GSK Investigational Site
-
Gettnau, Switzerland, 6142
- GSK Investigational Site
-
Jegenstorf, Switzerland, 3303
- GSK Investigational Site
-
Lugano, Switzerland, 6900
- GSK Investigational Site
-
Luzern, Switzerland, 6004
- GSK Investigational Site
-
Pregassona, Switzerland, 6963
- GSK Investigational Site
-
Salmsach, Switzerland, 8599
- GSK Investigational Site
-
St. Maurice, Switzerland, 1890
- GSK Investigational Site
-
Steckborn, Switzerland, 8266
- GSK Investigational Site
-
Winterthur, Switzerland, 8400
- GSK Investigational Site
-
Winterthur, Switzerland, 8405
- GSK Investigational Site
-
Zürich, Switzerland, 8046
- GSK Investigational Site
-
Zürich, Switzerland, 8050
- GSK Investigational Site
-
-
-
-
-
Bristol, United Kingdom, BS2 8HW
- GSK Investigational Site
-
Leeds, United Kingdom, LS12 1JE
- GSK Investigational Site
-
Sheffield, United Kingdom, S5 7AU
- GSK Investigational Site
-
-
Lanarkshire
-
Glasgow, Lanarkshire, United Kingdom, G3 8YJ
- GSK Investigational Site
-
Glasgow, Lanarkshire, United Kingdom, G69 7AD
- GSK Investigational Site
-
-
Lancashire
-
Blackpool, Lancashire, United Kingdom, FY4 3AD
- GSK Investigational Site
-
-
Somerset
-
Bath, Somerset, United Kingdom, BA1 3NG
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Body mass index > or = to 25 kg/m2.
- HbA1c > or =7% and < or =10% at screening.
- FPG > or = 7.0mmol/L (126mg/dL) at visit 2.
- Receiving at least 0.85g of metformin at constant dose(s) for at least 8 weeks prior to visit 1a.
- Female subjects must be postmenopausal or using effective contraceptive measures.
Exclusion criteria:
- Use of any other oral antidiabetic drug other than metformin within 12 weeks prior to screening.
- Subjects with clinically significant ongoing oedema requiring pharmacological treatment or with a history of oedema requiring pharmacological treatment.
- Subjects with a history of severe hypoglycaemia.
- Renal disease or renal dysfunction.
- Presence of clinically significant hepatic disease.
- Presence of unstable or severe angina or known NYHA grade I-IV congestive heart failure.
- Subjects who have had a previous myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft or cerebrovascular accident within 3 months prior to screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Change in HbA1c level from baseline following 52 weeks of treatment.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
CRP
|
|
insulin sensitivity
|
|
beta cell function
|
|
Change in FPG (fasting plasma glucose)
|
|
change in PAI-1
|
|
number of hypoglycaemic events
|
|
Change in 24 hr ABPM
|
|
Diabetes treatment satisfaction.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: GSK Clinical Trials, DM, FRCP, GlaxoSmithKline
Study record dates
Study Major Dates
Study Start
Study Start
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AVM100264
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.